Source comparison
BPC-157 vs Other Regenerative Peptides: Recovery Context
BPC-157 VEGF upregulation, fibroblast migration, collagen I synthesis Days 0–7 (early proliferative) 200–500 mcg/kg daily, split dose 40–68% faster functional recovery in animal models Best for acute ligament tears when started within 72 hours. Works by improv
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF upregulation, fibroblast migration, collagen I synthesis
- Days 0–7 (early proliferative)
- 200–500 mcg/kg daily, split dose
- 40–68% faster functional recovery in animal models
- Best for acute ligament tears when started within 72 hours. Works by improving collagen alignment during deposition
- TB-500 (Thymosin Beta-4)
- Actin regulation, cell migration, anti-inflammatory
- Days 3–14 (mid-proliferative)
- 2–5 mg twice weekly
- 25–35% reduction in healing time in tendon models
- Broader tissue repair signal. Less ligament-specific than BPC-157 but useful for multi-tissue injuries
- GHK-Cu (Copper Peptide)
- Matrix metalloproteinase modulation, collagen remodeling
- Days 21+ (remodeling phase)
- 1–3 mg daily, topical or subq
- Minimal acute phase benefit; 15–20% improvement in long-term scar quality
- Not for acute ligament tears. Use in late remodeling to refine scar tissue quality over months
- IGF-1 LR3
- Satellite cell activation, protein synthesis
- Days 14+ (late proliferative/early remodeling)
- 40–80 mcg daily
- 30–50% increase in cross-sectional area of repaired tissue
- Primarily muscle regeneration. Minimal direct ligament benefit unless combined with mechanical loading
- BPC-157 for ligament tear stands out because it targets the vascular and fibroblast recruitment bottleneck that limits early-phase healing. TB-500 overlaps in timing but works through different pathways (actin-based cell motility rather than growth factor signaling). GHK-Cu and IGF-1 belong to later phases. Using them in the first two weeks post-injury wastes the acute intervention window.